Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-) β-L- 2',3',dideoxy-3'-thiacytidine

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3179-3186

  King, Robert W ^a,b   Ladner, Stephanie K ^b   Miller, Thomas J ^b   Zaifert, Katie ^b   Perni, Robert B ^b   Conway, Sameul C ^b   Otto, Michael J ^b  

^a DUPONT COMPANY   (United States)

^b Avid Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FOSCARNET; LAMIVUDINE; N [1 (ALPHA CHLOROBENZYLIDENE) 2 OXO 2 (1 PIPERIDINYL)ETHYL]BENZAMIDE; PHENYLPROPENAMIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG EFFICACY; HEPATITIS B VIRUS; HEPATOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0031758695     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3179     Document Type: Article

References (30)

1. Acs, G., A. Sells, R. H. Purcell, P. Price, R. Engle, M. Shapiro, and M. Popper. 1987. Hepatitis B virus produced by transfected HepG2 cells causes hepatitis in chimpanzees. Proc. Natl. Acad. Sci. USA 84:4641-4644.
2. Bartholomew, M. M., R. W. Jansen, L. J. Jeffers, K. R. Reddy, L. C. Johnson, H. Bunzenddahl, L. D. Condreay, A. G. Tzakis, E. R. Schiff, and N. A. Brown. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
3. Beasley, R. P., and L. Y. Hwang. 1984. Epidemiology of hepatocellular carcinoma, p. 209-224. In G. N. Vynas, J. L. Dienstag, and J. H. Hoofnagle (ed.), Viral hepatitis and liver disease. Grune and Stratton, New York, N.Y.
4. Deinstag, J. I., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis V infection. N. Engl. J. Med. 333:2921-2924.
5. Fallows, D. A. and S. P. Goff. 1995. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J. Virol. 69:3067-3073.
6. Fattovich, G., L. Brollo, A. Alberti, P. Pontisso, G. Giustina, and G. Realdi. 1988. Long-term follow-up of anti-HBe positive chronic active hepatitis B. Hepatology 8:1651-1654.
7. Gish, R. G., J. Y. N. Lau, L. Brooks, J. W. S. Fang, S. L. Steady, J. C. Imperial, R. Garcia-Kennedy, C. O. Esquivel, and E. B. Keefe. 1996. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 23:1-7.
8. Grellier, L., D. Mutimer, M. Ahmed, D. Brown, A. K. Burroughs, K. Tolles, P. McMaster, P. Beranek, F. Kennedy, H. Kibbler, P. McPhillips, E. Elias, and G. Dusheiko. 1996. 3TC prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215.
9. Honkoop, P., R. A. de Man, R. A. Heijtink, and S. W. Schalm. 1995. Hepatitis B reactivation after lamivudine. Lancet 346:1156-1157.
10. King, R. W., D. L. Winslow, S. Garber, H. T. Scarnati, L. Bachelor, S. Stack, and M. J. Otto. 1995. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility of protease inhibitors. Antivir. Res. 28:13-24.
11. King, R. W., and S. K. Ladner. The HepAD38 assay: a high through-put, cell based screen for the evaluation of compounds against hepatitis B virus. In D. Kinchington and R. F. Schinazi (ed.), Methods in cellular and molecular biology antiviral evaluation, in press. Humana Press, Totowa N.J.
12. Knowles, B. B., C. C. Howe, and D. P. Aden. 1980. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigens. Science 209:497-499.
13. Korba, B. E., and G. Milman. 1991. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antivir. Res. 15:217-228.
14. Korba, B. E., and J. L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antivir. Res. 19:55-70.
15. Ladner, S. K., M. J. Otto, C. S. Barker, K. Zaifert, G.-H. Wang, J.-T. Guo, C. Seeger, and R. W. King. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720.
16. Ladner, S. K., T. J. Miller, M. J. Otto, and R. W. King. 1998. The M539V HBV polymerase variation responsible for 3TC-resistance also confers cross-resistance to other nucleoside analogs. Antivir. Chem. Chemother. 9:65-72.
17. Ladner, S. K., T. J. Miller, and R. W. King. 1998. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 3TC and a reduced ability to synthesize viral DNA. Antimicrob. Agents Chemother. 42:2128-2131.
18. Lanford, R. E., L. Notvall, and B. Beames. 1995. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J. Virol. 69:4431-4439.
19. Lau, J. Y. N., and T. L. Wright. 1993. Molecular virology and pathogenesis of hepatitis B. Lancet 3452:1335-1340.
20. Ling, R., D. Mutimer, M. Ahmed, E. Boxall, E. Elias, M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase During therapy of transplant recipients with 3TC. Hepatology 24:711-713.
21. Otto, M. J., S. Garber, D. L. Winslow, C. D. Reid, P. Aldrich, P. K. Jadhav, C. E. Patterson, C. N. Hodge, and Y.-S. E. Cheng. 1993. In vitro isolation and identifcation of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc. Natl. Acad. Sci. USA 90:7543-7547.
22. Perni, R. B., S. C. Conway, S. K. Ladner, T. J. Miller, K. Zaifert, M. J. Otto, and R. W. King. Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. Submitted for publication.
23. Popper, H., D. A. Shafritz, and J. H. Hoofnagle. 1987. Relations of the hepatitis B virus carrier state to hepatocellular carcinoma. Hepatology 7:764-772.
24. Seeger, C., and J. Maragos. 1989. Molecular analysis of the function of direct repeats and a polypurine tract for plus-stranded DNA priming in woodchuck hepatitis virus. J. Virol. 63:1907-1915.
25. Seeger, C., E. H. Leber, L. K. Wiens, and J. Hu. 1996. Mutagenesis of a hepatitis B virus reverse transcriptase yields temperature-sensitive virus. Virology 222:430-439.
26. Sells, M. A., M.-L. Chen, and G. Acs. 1987. Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84:1005-1009.
27. Sells, M. A., A. Z. Zelent, M. Shvartsman, and G. Acs. 1988. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol. 62:2836-2844.
28. Summers, J., P. M. Smith, and H. L. Horwich. 1990. Hepadnavirus envelope protein regulate covalently closed circular DNA amplification. J. Virol. 64: 2819-2824.
29. Thomas, H. C. 1998. Treatment of hepatitis B viral infection, p. 817-822. In A. J. Zuckerman (ed.) Viral hepatitis and liver disease. Alan R. Liss, Inc., New York, N.Y.
30. Tipples, G. A., M. M. Ma, K. P. Gischer, V. G. Bain, N. M. Kneteman, and D. L. J. Tyrrell. 1996. Mutations in HBV RNA-dependent DNA polymerase confers resistance to 3TC in vitro. Hepatology 24:714-717.